Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 385

1.

Development of CNS metastases and survival in patients with inflammatory breast cancer.

Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK.

Cancer. 2018 Mar 26. doi: 10.1002/cncr.31336. [Epub ahead of print]

PMID:
29579338
2.

Neurocognitive deficits in older patients with cancer.

Edwards BJ, Zhang X, Sun M, Holmes HM, Ketonen L, Guha N, Khalil P, Song J, Kesler S, Shah JB, Tripathy D, Valero V, Champlin RE.

J Geriatr Oncol. 2018 Mar 9. pii: S1879-4068(18)30089-4. doi: 10.1016/j.jgo.2018.02.010. [Epub ahead of print]

PMID:
29530493
3.

The Beneficial Effects of Minimizing Blood Loss in Pancreatoduodenectomy.

Seykora TF, Ecker BL, McMillan MT, Maggino L, Beane JD, Fong ZV, Hollis RH, Jamieson NB, Javed AA, Kowalsky SJ, Kunstman JW, Malleo G, Poruk KE, Soares K, Valero V 3rd, Velu LKP, Watkins AA, Vollmer CM Jr.; Pancreas Fistula Study Group.

Ann Surg. 2018 Feb 27. doi: 10.1097/SLA.0000000000002714. [Epub ahead of print]

PMID:
29489483
4.

Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer.

van la Parra RFD, Tadros AB, Checka CM, Rauch GM, Lucci A Jr, Smith BD, Krishnamurthy S, Valero V, Yang WT, Kuerer HM.

Br J Surg. 2018 Apr;105(5):535-543. doi: 10.1002/bjs.10755. Epub 2018 Feb 21.

PMID:
29465744
5.

Factors associated with improved outcomes for metastatic inflammatory breast cancer patients.

Weiss A, Menen RS, Lin HY, Shen Y, Rosso KJ, Shaitelman S, Woodward W, Valero V, Ueno NT, Bedrosian I, Babiera G.

Breast Cancer Res Treat. 2018 Feb 19. doi: 10.1007/s10549-018-4715-0. [Epub ahead of print]

PMID:
29460033
6.

Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes.

Palau A, Garz AK, Diesch J, Zwick A, Malinverni R, Valero V, Lappin K, Casquero R, Lennartsson A, Zuber J, Navarro T, Mills KI, Götze KS, Buschbeck M.

Oncotarget. 2017 Dec 1;8(70):115002-115017. doi: 10.18632/oncotarget.22839. eCollection 2017 Dec 29.

7.

A phase II study of tipifarnib and gemcitabine in metastatic breast cancer.

Yam C, Murthy RK, Valero V, Szklaruk J, Shroff GS, Stalzer CJ, Buzdar AU, Murray JL, Yang W, Hortobagyi GN, Moulder SL, Arun B.

Invest New Drugs. 2018 Apr;36(2):299-306. doi: 10.1007/s10637-018-0564-2. Epub 2018 Jan 27.

PMID:
29374384
8.

A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity.

Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK.

NPJ Breast Cancer. 2017 Dec 6;3:49. doi: 10.1038/s41523-017-0052-4. eCollection 2017.

9.

Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity.

Reddy SM, Barcenas CH, Sinha AK, Hsu L, Moulder SL, Tripathy D, Hortobagyi GN, Valero V.

Br J Cancer. 2018 Jan;118(1):17-23. doi: 10.1038/bjc.2017.379. Epub 2017 Dec 12.

10.

Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience.

Edwards BJ, Sun M, Zhang X, Holmes HM, Song J, Khalil P, Karuturi M, Shah JB, Dinney CP, Gagel RF, Valero V, Champlin RE, Tripathy D, Murphy WA Jr.

Support Care Cancer. 2018 May;26(5):1561-1568. doi: 10.1007/s00520-017-3962-7. Epub 2017 Dec 2.

PMID:
29197959
11.

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.

Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D.

Lancet Oncol. 2018 Jan;19(1):115-126. doi: 10.1016/S1470-2045(17)30716-7. Epub 2017 Nov 23.

PMID:
29175149
12.

Optimal Selection of Breast Cancer Patients for Elimination of Surgery Following Neoadjuvant Systemic Therapy.

Kuerer HM, Krishnamurthy S, Rauch GM, Yang WT, Smith BD, Valero V.

Ann Surg. 2017 Oct 23. doi: 10.1097/SLA.0000000000002573. [Epub ahead of print] No abstract available.

PMID:
29064904
13.

MacroH2A1.1 regulates mitochondrial respiration by limiting nuclear NAD+ consumption.

Posavec Marjanović M, Hurtado-Bagès S, Lassi M, Valero V, Malinverni R, Delage H, Navarro M, Corujo D, Guberovic I, Douet J, Gama-Perez P, Garcia-Roves PM, Ahel I, Ladurner AG, Yanes O, Bouvet P, Suelves M, Teperino R, Pospisilik JA, Buschbeck M.

Nat Struct Mol Biol. 2017 Nov;24(11):902-910. doi: 10.1038/nsmb.3481. Epub 2017 Oct 9.

14.

Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy.

Chaoul A, Milbury K, Spelman A, Basen-Engquist K, Hall MH, Wei Q, Shih YT, Arun B, Valero V, Perkins GH, Babiera GV, Wangyal T, Engle R, Harrison CA, Li Y, Cohen L.

Cancer. 2018 Jan 1;124(1):36-45. doi: 10.1002/cncr.30938. Epub 2017 Sep 20.

PMID:
28940301
15.

Identification of an Optimal Cut-off for Drain Fluid Amylase on Postoperative Day 1 for Predicting Clinically Relevant Fistula after Distal Pancreatectomy: A Multi-Institutional Analysis and External Validation.

Maggino L, Malleo G, Bassi C, Allegrini V, Beane JD, Beckman RM, Chen B, Dickson EJ, Drebin JA, Ecker BL, Fraker DL, House MG, Jamieson NB, Javed AA, Kowalsky SJ, Lee MK, McMillan MT, Roses RE, Salvia R, Valero V 3rd, Velu LKP, Wolfgang CL, Zureikat AH, Vollmer CM Jr.

Ann Surg. 2017 Sep 21. doi: 10.1097/SLA.0000000000002532. [Epub ahead of print]

PMID:
28938266
16.

Risk factors for falls in older patients with cancer.

Zhang X, Sun M, Liu S, Leung CH, Pang L, Popat UR, Champlin R, Holmes HM, Valero V, Dinney CP, Tripathy D, Edwards BJ.

BMJ Support Palliat Care. 2018 Mar;8(1):34-37. doi: 10.1136/bmjspcare-2017-001388. Epub 2017 Aug 31.

PMID:
28860112
17.

Risk Factors and Mitigation Strategies for Pancreatic Fistula After Distal Pancreatectomy: Analysis of 2026 Resections From the International, Multi-institutional Distal Pancreatectomy Study Group.

Ecker BL, McMillan MT, Allegrini V, Bassi C, Beane JD, Beckman RM, Behrman SW, Dickson EJ, Callery MP, Christein JD, Drebin JA, Hollis RH, House MG, Jamieson NB, Javed AA, Kent TS, Kluger MD, Kowalsky SJ, Maggino L, Malleo G, Valero V 3rd, Velu LKP, Watkins AA, Wolfgang CL, Zureikat AH, Vollmer CM Jr.

Ann Surg. 2017 Aug 29. doi: 10.1097/SLA.0000000000002491. [Epub ahead of print]

PMID:
28857813
18.

Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index.

Zhang X, Sun M, McKoy JM, Bhulani NNA, Valero V, Barcenas CH, Popat UR, Sri MK, Shah JB, Dinney CP, Hedberg AM, Champlin R, Tripathy D, Holmes HM, Stroehlein JR, Edwards BJ.

J Geriatr Oncol. 2018 Jan;9(1):81-83. doi: 10.1016/j.jgo.2017.07.012. Epub 2017 Aug 24. No abstract available.

PMID:
28844850
19.

A Phase 2 Study of Preoperative Capecitabine and Concomitant Radiation in Women With Advanced Breast Cancer.

Woodward WA, Fang P, Arriaga L, Gao H, Cohen EN, Reuben JM, Valero V, Le-Petross H, Middleton LP, Babiera GV, Strom EA, Tereffe W, Hoffman K, Smith BD, Buchholz TA, Perkins GH.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):777-783. doi: 10.1016/j.ijrobp.2017.04.030. Epub 2017 May 3.

PMID:
28843370
20.

Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.

Aapro M, Boccia R, Leonard R, Camps C, Campone M, Choquet S, Danova M, Glaspy J, Hus I, Link H, Sliwa T, Tesch H, Valero V.

Support Care Cancer. 2017 Nov;25(11):3295-3304. doi: 10.1007/s00520-017-3842-1. Epub 2017 Aug 25. Review.

21.

Pancreatogastrostomy Vs. Pancreatojejunostomy: a Risk-Stratified Analysis of 5316 Pancreatoduodenectomies.

Ecker BL, McMillan MT, Maggino L, Allegrini V, Asbun HJ, Ball CG, Bassi C, Beane JD, Behrman SW, Berger AC, Bloomston M, Callery MP, Christein JD, Dickson E, Dixon E, Drebin JA, Castillo CF, Fisher WE, Fong ZV, Haverick E, Hollis RH, House MG, Hughes SJ, Jamieson NB, Kent TS, Kowalsky SJ, Kunstman JW, Malleo G, Salem RR, Soares KC, Valero V 3rd, Watkins AA, Wolfgang CL, Zureikat AH, Vollmer CM Jr.

J Gastrointest Surg. 2018 Jan;22(1):68-76. doi: 10.1007/s11605-017-3547-2. Epub 2017 Aug 24. No abstract available.

PMID:
28840459
22.

Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation.

Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK.

J Cancer. 2017 Jul 5;8(11):2004-2009. doi: 10.7150/jca.18196. eCollection 2017.

23.

Analysis of stereotactic biopsies performed on suspicious calcifications identified within 24 months after completion of breast conserving surgery and radiation therapy for early breast cancer: Can biopsy be obviated?

Candelaria RP, Hansakul P, Thompson AM, Le-Petross H, Valero V, Bassett R, Huang ML, Santiago L, Adrada BE.

Am J Surg. 2018 Apr;215(4):693-698. doi: 10.1016/j.amjsurg.2017.06.032. Epub 2017 Jul 1.

PMID:
28712671
24.

Circulating Epithelial Cells in Intraductal Papillary Mucinous Neoplasms and Cystic Pancreatic Lesions.

Poruk KE, Valero V 3rd, He J, Ahuja N, Cameron JL, Weiss MJ, Lennon AM, Goggins M, Wood LD, Wolfgang CL.

Pancreas. 2017 Aug;46(7):943-947. doi: 10.1097/MPA.0000000000000869.

PMID:
28697136
25.

Skin Necrosis After Ado-Trastuzumab Emtansine Extravasation.

Shafaee MN, Salahudeen AA, Valero V.

J Oncol Pract. 2017 Aug;13(8):555-556. doi: 10.1200/JOP.2016.020198. Epub 2017 Jul 5. No abstract available.

PMID:
28678590
26.

Characterization and Optimal Management of High-risk Pancreatic Anastomoses During Pancreatoduodenectomy.

Ecker BL, McMillan MT, Asbun HJ, Ball CG, Bassi C, Beane JD, Behrman SW, Berger AC, Dickson EJ, Bloomston M, Callery MP, Christein JD, Dixon E, Drebin JA, Castillo CF, Fisher WE, Fong ZV, Haverick E, Hollis RH, House MG, Hughes SJ, Jamieson NB, Javed AA, Kent TS, Kowalsky SJ, Kunstman JW, Malleo G, Poruk KE, Salem RR, Schmidt CR, Soares K, Stauffer JA, Valero V, Velu LKP, Watkins AA, Wolfgang CL, Zureikat AH, Vollmer CM Jr.

Ann Surg. 2018 Apr;267(4):608-616. doi: 10.1097/SLA.0000000000002327.

PMID:
28594741
27.

A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.

Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Black DM, Santiago L, Hobbs BP, Lucci A Jr, Gilcrease M, Hwang RF, Candelaria RP, Chavez-MacGregor M, Smith BD, Arribas E, Moseley T, Teshome M, Miggins MV, Valero V, Hunt KK, Yang WT.

Ann Surg. 2018 May;267(5):946-951. doi: 10.1097/SLA.0000000000002313.

PMID:
28549010
28.

Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.

Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Lucci A Jr, Caudle AS, DeSnyder SM, Teshome M, Barcenas CH, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM.

JAMA Surg. 2017 Jul 1;152(7):665-670. doi: 10.1001/jamasurg.2017.0562.

PMID:
28423171
29.

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer.

Castrellon AB, Pidhorecky I, Valero V, Raez LE.

Oncol Rev. 2017 Mar 17;11(1):324. doi: 10.4081/oncol.2017.324. eCollection 2017 Mar 3. Review.

30.

Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.

Fouad TM, Barrera AMG, Reuben JM, Lucci A, Woodward WA, Stauder MC, Lim B, DeSnyder SM, Arun B, Gildy B, Valero V, Hortobagyi GN, Ueno NT.

Lancet Oncol. 2017 Apr;18(4):e228-e232. doi: 10.1016/S1470-2045(17)30192-4. Review.

PMID:
28368261
31.

MacroH2A histone variants maintain nuclear organization and heterochromatin architecture.

Douet J, Corujo D, Malinverni R, Renauld J, Sansoni V, Posavec Marjanović M, Cantariño N, Valero V, Mongelard F, Bouvet P, Imhof A, Thiry M, Buschbeck M.

J Cell Sci. 2017 May 1;130(9):1570-1582. doi: 10.1242/jcs.199216. Epub 2017 Mar 10.

32.

Identification of frequent somatic mutations in inflammatory breast cancer.

Matsuda N, Lim B, Wang Y, Krishnamurthy S, Woodward W, Alvarez RH, Lucci A, Valero V, Reuben JM, Meric-Bernstam F, Ueno NT.

Breast Cancer Res Treat. 2017 Jun;163(2):263-272. doi: 10.1007/s10549-017-4165-0. Epub 2017 Feb 27.

PMID:
28243898
33.

Molecular Profiling Using Breast Cancer Subtype to Plan for Breast Reconstruction.

Sandberg LJ, Clemens MW, Symmans WF, Valero V, Caudle AS, Smith B, Kuerer HM, Hsu L, Kronowitz SJ.

Plast Reconstr Surg. 2017 Mar;139(3):586e-596e. doi: 10.1097/PRS.0000000000003050.

PMID:
28234813
34.

Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.

Barcenas CH, Raghavendra A, Sinha AK, Syed MP, Hsu L, Patangan MG Jr, Chavez-MacGregor M, Shen Y, Hortobagyi GH, Valero V, Giordano SH, Ueno NT, Tripathy D.

Cancer. 2017 Jul 1;123(13):2422-2431. doi: 10.1002/cncr.30618. Epub 2017 Feb 15.

PMID:
28199747
35.

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.

Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN.

J Clin Oncol. 2017 Apr 1;35(10):1049-1060. doi: 10.1200/JCO.2015.63.1010. Epub 2017 Jan 30.

36.

Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.

Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL 3rd, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL.

JAMA Oncol. 2017 Apr 1;3(4):509-515. doi: 10.1001/jamaoncol.2016.5281.

PMID:
27893038
37.

Clinical outcomes based on multigene profiling in metastatic breast cancer patients.

Basho RK, de Melo Gagliato D, Ueno NT, Wathoo C, Chen H, Shariati M, Wei C, Alvarez RH, Moulder SL, Sahin AA, Roy-Chowdhuri S, Chavez-MacGregor M, Litton JK, Valero V, Luthra R, Zeng J, Shaw KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Bernstam F.

Oncotarget. 2016 Nov 22;7(47):76362-76373. doi: 10.18632/oncotarget.12987.

38.

The Impact of Paravertebral Block Analgesia on Breast Cancer Survival After Surgery.

Cata JP, Chavez-MacGregor M, Valero V, Black W, Black DM, Goravanchi F, Ifeanyi IC, Hernandez M, Rodriguez-Restrepo A, Gottumukkala V.

Reg Anesth Pain Med. 2016 Nov/Dec;41(6):696-703.

PMID:
27685344
39.

Predictors of left ventricular systolic function recovery in the setting of sinus tachycardia in patients with cancer.

Hassan SA, Yusuf SW, Sharma J, Khan J, Guindani M, Valero V, Chavez-McGregor M, Banchs J.

Echocardiography. 2017 Jan;34(1):29-36. doi: 10.1111/echo.13372. Epub 2016 Oct 21.

PMID:
27767228
40.

HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.

Press MF, Sauter G, Buyse M, Fourmanoir H, Quinaux E, Tsao-Wei DD, Eiermann W, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Mackey JR, Bee V, Ma Y, Villalobos I, Campeau A, Mirlacher M, Lindsay MA, Slamon DJ.

J Clin Oncol. 2016 Oct 10;34(29):3518-3528. doi: 10.1200/JCO.2016.66.6693.

41.

Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer.

Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, Ueno NT, Hortobagyi GN, Chavez-MacGregor M.

Breast Cancer Res Treat. 2016 Sep;159(2):367-74. doi: 10.1007/s10549-016-3933-6. Epub 2016 Aug 13.

PMID:
27522517
42.

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors.

Wheler JJ, Atkins JT, Janku F, Moulder SL, Stephens PJ, Yelensky R, Valero V, Miller V, Kurzrock R, Meric-Bernstam F.

Oncoscience. 2016 Jun 30;3(5-6):164-72. doi: 10.18632/oncoscience.307. eCollection 2016.

43.

Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer.

Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Tin S, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, Alvarez RH, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M, Reuben JM.

Oncotarget. 2017 May 30;8(22):35656-35668. doi: 10.18632/oncotarget.10290.

44.

Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer.

Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Sanda T, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, Alvarez RH, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M, Reuben JM.

J Cancer. 2016 Jun 3;7(9):1095-104. doi: 10.7150/jca.13098. eCollection 2016.

45.

T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab.

Dzimitrowicz H, Berger M, Vargo C, Hood A, Abdelghany O, Raghavendra AS, Tripathy D, Valero V, Hatzis C, Pusztai L, Murthy R.

J Clin Oncol. 2016 Oct 10;34(29):3511-3517. doi: 10.1200/JCO.2016.67.3624.

PMID:
27298406
46.

Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer.

Arun BK, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J, Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, Heckman-Stoddard BM, Koenig KB, Alvarez RR, Murray JL, Valero V, Lippman SM, Brown P, Sneige N.

Breast Cancer Res Treat. 2016 Jul;158(1):67-77. doi: 10.1007/s10549-016-3849-1. Epub 2016 Jun 10.

PMID:
27287781
47.

Downregulation of the Deiminase PADI2 Is an Early Event in Colorectal Carcinogenesis and Indicates Poor Prognosis.

Cantariño N, Musulén E, Valero V, Peinado MA, Perucho M, Moreno V, Forcales SV, Douet J, Buschbeck M.

Mol Cancer Res. 2016 Sep;14(9):841-8. doi: 10.1158/1541-7786.MCR-16-0034. Epub 2016 Jun 8.

48.

Incorporation of Procedure-specific Risk Into the ACS-NSQIP Surgical Risk Calculator Improves the Prediction of Morbidity and Mortality After Pancreatoduodenectomy.

McMillan MT, Allegrini V, Asbun HJ, Ball CG, Bassi C, Beane JD, Behrman SW, Berger AC, Bloomston M, Callery MP, Christein JD, Dickson E, Dixon E, Drebin JA, Fernandez-Del Castillo C, Fisher WE, Fong ZV, Haverick E, Hollis RH, House MG, Hughes SJ, Jamieson NB, Kent TS, Kowalsky SJ, Kunstman JW, Malleo G, McElhany AL, Salem RR, Soares KC, Sprys MH, Valero V 3rd, Watkins AA, Wolfgang CL, Zureikat AH, Vollmer CM Jr.

Ann Surg. 2017 May;265(5):978-986. doi: 10.1097/SLA.0000000000001796.

PMID:
27232260
49.

Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory Breast Cancer.

Loveland-Jones C, Lin H, Shen Y, Bedrosian I, Shaitelman S, Kuerer H, Woodward W, Ueno N, Valero V, Babiera G.

Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1218-25. doi: 10.1016/j.ijrobp.2016.02.065. Epub 2016 Mar 10.

PMID:
27209502
50.

A cellular model reflecting the phenotypic heterogeneity of mutant HRAS driven squamous cell carcinoma.

Cantariño N, Fernández-Figueras MT, Valero V, Musulén E, Malinverni R, Granada I, Goldie SJ, Martín-Caballero J, Douet J, Forcales SV, Buschbeck M.

Int J Cancer. 2016 Sep 1;139(5):1106-16. doi: 10.1002/ijc.30139. Epub 2016 May 5.

Supplemental Content

Loading ...
Support Center